Latest Regulatory Approvals News

S2 Resources and Black Raven Mining have signed a key Heritage Protection Agreement with the Wajarri Yamaji people, paving the way for exploration licences to be granted over the highly prospective Jillewarra Project in Western Australia.

Vita Resources has secured a pivotal recommendation from Yukon authorities to proceed with a five-year exploration program at its ICE Copper-Gold Project, marking a significant step forward in its Canadian mining ambitions.

Sarytogan Graphite Limited has received over $2 million from key investor Dias Sarsenov, advancing its share placement strategy and preparing for a pivotal board appointment. Meanwhile, a significant top-up investment from the EBRD awaits shareholder approval.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

Bass Oil has received regulatory approval to award the drilling contract for its Bunian 6 well in Indonesia, aiming to add 500 barrels of oil per day to current production by mid-year.

Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

Horizon Oil has released a first supplementary and replacement bidder’s statement for its off-market takeover offer for Cue Energy, proposing a mix of cash and shares that values Cue at a 10-14% premium. The deal aims to create a diversified oil and gas producer across Asia-Pacific with significant synergies.

Lakes Blue Energy has temporarily halted gas flow testing at its Wombat-5 well to conduct extended pressure analysis, planning a perforation program to enhance production prospects.

Chimeric Therapeutics Limited has announced a significant 100-to-1 security consolidation affecting shares, options, and performance rights, pending shareholder approval and set for implementation in April 2026.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

Neometals Ltd has released a positive scoping study for its Ironclad gold deposit at the Barrambie Gold Project, outlining a rapid production pathway with potential output of up to 11,000 ounces of gold within a year.